Itama Ranoraya (IRRA) won a contract for 111 million ADS syringes for Covid-19 vaccination

ILLUSTRATION. Medical device products distributed by PT Itama Ranoraya Tbk (IRRA)

Reporter: Arfyana Citra Rahayu | Editor: Handoyo.

KONTAN.CO.ID – JAKARTA. PT Itama Ranoraya Tbk (IRRA) again received an order for the procurement of Auto Disable Syringe (ADS) syringes from the government. On November 27, 2020, IRRA signed a Sales and Purchase Agreement (SPA) contract for 111 million pieces of ADS syringes.

President Director Itama Ranoraya, Heru Firdausi Syarif, said that the contract for the supply of syringes of 111 million pieces was the second order from the Government.

Previously in the third quarter of 2020, IRRA received an order from the government (Ministry of Health) for 35 million pieces of 0.5 ml and 0.05 ml ADS syringes for the immunization vaccine program.

“On November 27, 2020, we have signed the provision of 111 million pieces of 0.5 ml ADS syringes with the Ministry of Health. And the procurement is for the preparation of the Government’s Covid-19 vaccine program, “he explained in an official statement on Sunday (29/11).

The ADS IRRA syringe is claimed to be a WHO standard product with a Domestic Component Level (TKDN) above 60%. The production itself is carried out by PT Oneject Indonesia (Oneject) which is the sister company of IRRA.

Just so you know, the ADS syringe product is currently a mandatory product for the immunization vaccine program, including the Covid-19 vaccine. The WHO (World Health Organization) UN health agency has declared 2020 as the first year for the use of safe syringes worldwide.

Also Read: There is a Covid-19 vaccination program, this is the business prospect of Itama Ranoraya (IRRA) in 2021

This WHO policy is what initiated Oneject to add capacity in October 2019, before the Covid-19 pandemic. In October last year, Oneject started building a second factory to increase its production capacity by building a new factory in Cikarang Bekasi with a capacity of 900 million, bringing the total capacity to 1.2 billion syringes per year.

Director of Marketing and Sales of IRRA Hendry Herman said that currently the use of ADS syringes in Indonesia is still around 20% and 80% is still in the form of conventional syringes. As for the ADS market, IRRA has a market share of up to 70%. With the existence of the WHO program, it is a growth for ADS products not only in Indonesia but globally.

“So before the Covid-19 pandemic, we believe the demand for ADS syringes will continue to increase with the WHO program. And this year there was a Covid-19 Pandemic, which was followed by the Covid-19 vaccine program globally including Indonesia, so the use of needles for next year will increase or there will be a windfall for the demand for Covid-19 vaccine syringes, “said Hendry.

Therefore, Hendry emphasized, it is necessary to accelerate production to anticipate these needs.

For information, in the first semester of 2021 Oneject’s production could reach 600 million pieces of syringes / year and at the end of the second semester the production could reach 1.2 billion / year. This target is much faster than the original plan where the capacity of 1.2 billion / new year will be achieved in 2024.